Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Average Rating of “Buy” from Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has been assigned an average recommendation of “Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $25.83.

CNTA has been the topic of several recent research reports. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. Guggenheim upped their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, CTO Tia L. Bush sold 17,813 shares of Centessa Pharmaceuticals stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $18.00, for a total value of $320,634.00. Following the transaction, the chief technology officer now owns 147,615 shares in the company, valued at $2,657,070. This trade represents a 10.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Saurabh Saha sold 87,496 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $18.46, for a total value of $1,615,176.16. Following the sale, the chief executive officer now owns 575,661 shares of the company’s stock, valued at approximately $10,626,702.06. The trade was a 13.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 392,484 shares of company stock worth $6,723,523. 11.59% of the stock is owned by company insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC increased its position in shares of Centessa Pharmaceuticals by 59.2% in the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock worth $43,168,000 after acquiring an additional 1,778,515 shares in the last quarter. Farallon Capital Management LLC boosted its position in Centessa Pharmaceuticals by 438.0% during the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock worth $18,024,000 after purchasing an additional 1,625,000 shares during the period. Janus Henderson Group PLC acquired a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at $20,698,000. Franklin Resources Inc. raised its position in Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after purchasing an additional 1,145,823 shares during the period. Finally, Driehaus Capital Management LLC lifted its stake in shares of Centessa Pharmaceuticals by 89.5% during the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after purchasing an additional 987,997 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ CNTA opened at $16.46 on Wednesday. The firm’s 50-day moving average is $16.79 and its two-hundred day moving average is $14.92. The company has a market capitalization of $2.17 billion, a PE ratio of -10.76 and a beta of 1.53. Centessa Pharmaceuticals has a 12-month low of $7.38 and a 12-month high of $18.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05. Equities analysts anticipate that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.